WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.
24th Annual Needham Virtual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: April 10, 2025
Time: 8:45 a.m. ET
Webcast: Click here
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
339-970-2843
Media
Jon Yu
ICR Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
475-395-5375
| Last Trade: | US$3.01 |
| Daily Volume: | 0 |
March 25, 2025 February 25, 2025 February 24, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
